PolyActiva is a pioneering biotechnology company developing drug-polymer conjugates that allow for site specific drug delivery from medical device components.

PolyActiva’s platform technology is used to deliver drugs to specific sites in the body and is particularly well suited to areas in the body that have limited volumes, for example the eye.

Established in 2010, the organisation has secured more than AU$10 million of investment and established a Melbourne base that provides core chemistry and development capabilities. It also works with key research service, including Monash Institute of Pharmaceutical Sciences, University of Melbourne, CERA, MSU, Bolder BioPATH, Institute of Bone and Joint Research, and Miguel Hernandez University to provide capabilities in pharmaceutical chemistry, polymer chemistry, ophthalmology and animal models.

For more information, visit the PolyActiva website here